|By Marketwired .||
|September 19, 2013 08:45 AM EDT||
SAN FRANCISCO, CA -- (Marketwired) -- 09/19/13 -- Despite all of the advances in diagnosis and treatment, the family of diseases that falls under the umbrella of "cancer" still represents a significant unmet medical need. Consequently, research continues in the discovery and development of therapeutic agents with novel mechanisms of action, wider therapeutic indexes and lower overall toxicities. In this interview with The Life Sciences Report, Peter Culpepper, CFO and COO of Provectus Pharmaceuticals Inc. (OTCQB: PVCT), describes his company's innovative rose bengal formulation and its use as a cancer therapeutic.
The Life Sciences Report: Rose bengal is commonly known as a dye. Can you tell me about the history of this compound as a therapeutic agent?
Peter Culpepper: Rose bengal is a very unusual compound. It was originally used as a textile dye in the late 1800s, and later found a wide variety of diagnostic applications. There are more than 3,500 peer-reviewed publications describing the use of rose bengal in staining diseased tissue or identifying tissue irregularities.
Provectus Pharmaceuticals Inc. has determined how to use rose bengal therapeutically -- the first to do so. In the late nineties, and after more than a hundred years of diagnostic use, we identified rose bengal's therapeutic potential for treating cancers and serious skin diseases by taking advantage of its photosensitivity characteristics....
Continue reading this interview with Peter Culpepper: Provectus Pharmaceuticals Inc. and PV-10: Rose Bengal as a Novel Cancer Therapeutic
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.
Provectus Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Provectus Pharmaceuticals Inc. had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Provectus Pharmaceuticals Inc. and not Streetwise Reports or The Life Sciences Report or its officers.
Streetwise Reports, LLC - The Life Sciences Report
Email: Email Contact